CDER's Rejection Of Larger Bromday Bottle Rests On Hypothetical Risk, ISTA Says

FDA drug reviewers’ rejection of a larger fill size for ISTA Pharmaceuticals’ ocular agent Bromday (bromfenac ophthalmic solution 0.09%) was based on a hypothetical risk from a use that is contrary to product labeling, the company says.